Gryphon Investors acquired Synteract

Sep. 2008

Client: Synteract is a mid-sized Contract Research Organization (CRO) focused on central nervous system (CNS) and Oncology Trials

Role: Edgemont Partners acted as exclusive financial advisor to Gryphon Investors in its acquisition of Synteract from Celerity Partners

Location: Carlsbad, CA

Sector: Pharmaceutical Services

Lead Banker: David Blume

View Press Release

gryphon investors logo


synteract logo
Get In Touch